Preclinical evidences suggest new treatment options for endocrine disorders: Pasireotide (SOM230) and Everolimus (RAD001)
Gespeichert in:
| Veröffentlicht in: | Annales d'endocrinologie 2008-04, Vol.69 (2), p.162-163 |
|---|---|
| 1. Verfasser: | |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 163 |
|---|---|
| container_issue | 2 |
| container_start_page | 162 |
| container_title | Annales d'endocrinologie |
| container_volume | 69 |
| creator | Schmid, H.A |
| description | |
| doi_str_mv | 10.1016/j.ando.2008.02.020 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_69185297</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>1_s2_0_S0003426608000577</els_id><sourcerecordid>69185297</sourcerecordid><originalsourceid>FETCH-LOGICAL-c439t-a96dc9f94e81b7ab8890f896020971855cac5ecf442505225dbb60f456b0da1a3</originalsourceid><addsrcrecordid>eNp9kk1vFDEMhucAoqXlD3BAuYDawy5O5itBCKkq5UMqakXhHGUST5VlNlnima3235PRLiBxQLKUHF6_th-7KJ5zWHLgzevV0gQXlwJALkHkgEfFMQCUi0o0zVHxlGgFwIUs5ZPiiMuKt6Cq42J3m9AOPnhrBoZb7zBYJEbT_T3SyAI-sDGhGdcYRhY3o4-BWB8Tw1zOJh-QOU8xOUz0ht0a8gnjmG3Y2d3NF1HCOcuNsastpjj49UTs7OvF-9zJ-WnxuDcD4bPDe1J8_3D17fLT4vrm4-fLi-uFrUo1LoxqnFW9qlDyrjWdlAp6qZo8oWq5rGtrbI22rypRQy1E7bqugb6qmw6c4aY8KV7tfTcp_pzyUHrtyeIwmIBxIt2o7CJUm4ViL7QpEiXs9Sb5tUk7zUHPkPVKz5D1DFmDyAE56cXBferW6P6mHAhnwcuDwFBm3CcTrKc_umwhy6aeq7_d6zCz2HpMmqyfl-EyUTtqF_3_-3j3T_rvrf7AHdIqTilkypprygn6bj6N-TJA5l_dtuUvzhexAg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>69185297</pqid></control><display><type>article</type><title>Preclinical evidences suggest new treatment options for endocrine disorders: Pasireotide (SOM230) and Everolimus (RAD001)</title><source>MEDLINE</source><source>ScienceDirect Journals (5 years ago - present)</source><creator>Schmid, H.A</creator><creatorcontrib>Schmid, H.A</creatorcontrib><identifier>ISSN: 0003-4266</identifier><identifier>DOI: 10.1016/j.ando.2008.02.020</identifier><identifier>PMID: 18417094</identifier><identifier>CODEN: ANENAG</identifier><language>eng</language><publisher>Paris: Elsevier Masson SAS</publisher><subject>Animals ; Biological and medical sciences ; Endocrine System Diseases - drug therapy ; Endocrinology & Metabolism ; Everolimus ; Fundamental and applied biological sciences. Psychology ; Humans ; Immunosuppressive Agents - therapeutic use ; Internal Medicine ; Oligopeptides - therapeutic use ; Protein Kinases - drug effects ; Receptors, Somatostatin - drug effects ; Sirolimus - analogs & derivatives ; Sirolimus - therapeutic use ; Somatostatin - analogs & derivatives ; TOR Serine-Threonine Kinases ; Vertebrates: endocrinology</subject><ispartof>Annales d'endocrinologie, 2008-04, Vol.69 (2), p.162-163</ispartof><rights>Elsevier Masson SAS</rights><rights>2008 Elsevier Masson SAS</rights><rights>2008 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c439t-a96dc9f94e81b7ab8890f896020971855cac5ecf442505225dbb60f456b0da1a3</citedby><cites>FETCH-LOGICAL-c439t-a96dc9f94e81b7ab8890f896020971855cac5ecf442505225dbb60f456b0da1a3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.ando.2008.02.020$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>309,310,314,780,784,789,790,3550,23930,23931,25140,27924,27925,45995</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=20383657$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/18417094$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Schmid, H.A</creatorcontrib><title>Preclinical evidences suggest new treatment options for endocrine disorders: Pasireotide (SOM230) and Everolimus (RAD001)</title><title>Annales d'endocrinologie</title><addtitle>Ann Endocrinol (Paris)</addtitle><subject>Animals</subject><subject>Biological and medical sciences</subject><subject>Endocrine System Diseases - drug therapy</subject><subject>Endocrinology & Metabolism</subject><subject>Everolimus</subject><subject>Fundamental and applied biological sciences. Psychology</subject><subject>Humans</subject><subject>Immunosuppressive Agents - therapeutic use</subject><subject>Internal Medicine</subject><subject>Oligopeptides - therapeutic use</subject><subject>Protein Kinases - drug effects</subject><subject>Receptors, Somatostatin - drug effects</subject><subject>Sirolimus - analogs & derivatives</subject><subject>Sirolimus - therapeutic use</subject><subject>Somatostatin - analogs & derivatives</subject><subject>TOR Serine-Threonine Kinases</subject><subject>Vertebrates: endocrinology</subject><issn>0003-4266</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2008</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kk1vFDEMhucAoqXlD3BAuYDawy5O5itBCKkq5UMqakXhHGUST5VlNlnima3235PRLiBxQLKUHF6_th-7KJ5zWHLgzevV0gQXlwJALkHkgEfFMQCUi0o0zVHxlGgFwIUs5ZPiiMuKt6Cq42J3m9AOPnhrBoZb7zBYJEbT_T3SyAI-sDGhGdcYRhY3o4-BWB8Tw1zOJh-QOU8xOUz0ht0a8gnjmG3Y2d3NF1HCOcuNsastpjj49UTs7OvF-9zJ-WnxuDcD4bPDe1J8_3D17fLT4vrm4-fLi-uFrUo1LoxqnFW9qlDyrjWdlAp6qZo8oWq5rGtrbI22rypRQy1E7bqugb6qmw6c4aY8KV7tfTcp_pzyUHrtyeIwmIBxIt2o7CJUm4ViL7QpEiXs9Sb5tUk7zUHPkPVKz5D1DFmDyAE56cXBferW6P6mHAhnwcuDwFBm3CcTrKc_umwhy6aeq7_d6zCz2HpMmqyfl-EyUTtqF_3_-3j3T_rvrf7AHdIqTilkypprygn6bj6N-TJA5l_dtuUvzhexAg</recordid><startdate>20080401</startdate><enddate>20080401</enddate><creator>Schmid, H.A</creator><general>Elsevier Masson SAS</general><general>Masson</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20080401</creationdate><title>Preclinical evidences suggest new treatment options for endocrine disorders: Pasireotide (SOM230) and Everolimus (RAD001)</title><author>Schmid, H.A</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c439t-a96dc9f94e81b7ab8890f896020971855cac5ecf442505225dbb60f456b0da1a3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2008</creationdate><topic>Animals</topic><topic>Biological and medical sciences</topic><topic>Endocrine System Diseases - drug therapy</topic><topic>Endocrinology & Metabolism</topic><topic>Everolimus</topic><topic>Fundamental and applied biological sciences. Psychology</topic><topic>Humans</topic><topic>Immunosuppressive Agents - therapeutic use</topic><topic>Internal Medicine</topic><topic>Oligopeptides - therapeutic use</topic><topic>Protein Kinases - drug effects</topic><topic>Receptors, Somatostatin - drug effects</topic><topic>Sirolimus - analogs & derivatives</topic><topic>Sirolimus - therapeutic use</topic><topic>Somatostatin - analogs & derivatives</topic><topic>TOR Serine-Threonine Kinases</topic><topic>Vertebrates: endocrinology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Schmid, H.A</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Annales d'endocrinologie</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Schmid, H.A</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Preclinical evidences suggest new treatment options for endocrine disorders: Pasireotide (SOM230) and Everolimus (RAD001)</atitle><jtitle>Annales d'endocrinologie</jtitle><addtitle>Ann Endocrinol (Paris)</addtitle><date>2008-04-01</date><risdate>2008</risdate><volume>69</volume><issue>2</issue><spage>162</spage><epage>163</epage><pages>162-163</pages><issn>0003-4266</issn><coden>ANENAG</coden><cop>Paris</cop><pub>Elsevier Masson SAS</pub><pmid>18417094</pmid><doi>10.1016/j.ando.2008.02.020</doi><tpages>2</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0003-4266 |
| ispartof | Annales d'endocrinologie, 2008-04, Vol.69 (2), p.162-163 |
| issn | 0003-4266 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_69185297 |
| source | MEDLINE; ScienceDirect Journals (5 years ago - present) |
| subjects | Animals Biological and medical sciences Endocrine System Diseases - drug therapy Endocrinology & Metabolism Everolimus Fundamental and applied biological sciences. Psychology Humans Immunosuppressive Agents - therapeutic use Internal Medicine Oligopeptides - therapeutic use Protein Kinases - drug effects Receptors, Somatostatin - drug effects Sirolimus - analogs & derivatives Sirolimus - therapeutic use Somatostatin - analogs & derivatives TOR Serine-Threonine Kinases Vertebrates: endocrinology |
| title | Preclinical evidences suggest new treatment options for endocrine disorders: Pasireotide (SOM230) and Everolimus (RAD001) |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-08T04%3A58%3A44IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Preclinical%20evidences%20suggest%20new%20treatment%20options%20for%20endocrine%20disorders:%20Pasireotide%20(SOM230)%20and%20Everolimus%20(RAD001)&rft.jtitle=Annales%20d'endocrinologie&rft.au=Schmid,%20H.A&rft.date=2008-04-01&rft.volume=69&rft.issue=2&rft.spage=162&rft.epage=163&rft.pages=162-163&rft.issn=0003-4266&rft.coden=ANENAG&rft_id=info:doi/10.1016/j.ando.2008.02.020&rft_dat=%3Cproquest_cross%3E69185297%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=69185297&rft_id=info:pmid/18417094&rft_els_id=1_s2_0_S0003426608000577&rfr_iscdi=true |